23,442 results on '"EVEROLIMUS"'
Search Results
202. Signal TrAnsduction Pathway Activity Analysis in OVarian cancER (STAPOVER)
- Author
-
Radboud University Medical Center, Erasmus Medical Center, Maastricht University Medical Center, InnoSIGN, Eurofins, and Jurgen M.J. Piek, MD, PhD
- Published
- 2023
203. Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy
- Published
- 2023
204. SnoRNA U50A mediates everolimus resistance in breast cancer through mTOR downregulation
- Author
-
Jie-Ning Li, Zhu-Jun Loh, Hui-Wen Chen, I-Ying Lee, Jui-Hung Tsai, and Pai-Sheng Chen
- Subjects
Breast cancer ,mTOR ,Everolimus ,snoRNAs ,U50A ,Drug resistance ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Breast cancer remains the most prevalent cancer in women globally, posing significant challenges in treatment due to the inevitable development of resistance to targeted therapies like everolimus, an mTOR inhibitor. While several mechanisms of resistance have been proposed, the role of snoRNAs in this context remains inadequately explored. Our study unveils a novel connection between snoRNAs and everolimus resistance, focusing on the snoRNA U50A. We discovered that U50A negatively regulates mTOR signaling by transcriptionally downregulating mTOR gene expression, which consequently leads to decreased sensitivity to everolimus treatment. Through RNA sequencing, gene set enrichment analyses, and experimental validations, we established that U50A overexpression in breast cancer cells results in mTOR downregulation and subsequently, everolimus desensitization. Clinical results further supported our findings, showing a higher prevalence of everolimus resistance in tumors with elevated U50A expression. Moreover, our results suggest that U50A's effect on mTOR is mediated through the suppression of the transcription factors c-Myc, with a notable impact on cancer cell viability under everolimus treatment. This study not only highlights the complex role of snoRNAs in cancer drug resistance but also proposes U50A as a potential biomarker for predicting everolimus efficacy in breast cancer treatment.
- Published
- 2024
- Full Text
- View/download PDF
205. Targeting the mTOR Pathway for the Prevention of ER-negative Breast Cancer
- Author
-
Mazumdar, Abhijit, Tahaney, William M, Hill, Jamal L, Zhang, Yun, Ramachandran, Sumankalai, Kawedia, Jitesh, Qian, Jing, Contreras, Alejandro, Savage, Michelle I, Vornik, Lana A, Sei, Shizuko, Mohammed, Altaf, and Brown, Powel H
- Subjects
Cancer ,Breast Cancer ,Prevention ,Humans ,Mice ,Animals ,Female ,Receptors ,Estrogen ,TOR Serine-Threonine Kinases ,Mammary Neoplasms ,Animal ,Everolimus ,Breast Neoplasms ,Clinical Sciences ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
Our results show that everolimus delays mammary tumor formation in multiple mouse models, suggesting that mTOR inhibitors will be useful for the prevention of ER-negative and triple-negative breast cancer in humans. See related Spotlight, p. 787.
- Published
- 2022
206. A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck.
- Author
-
Nathan, Cherie-Ann O, Hayes, D Neil, Karrison, Theodore, Harismendy, Olivier, Flores, José M, Moore-Medlin, Tara, Vokes, Everett E, Gutkind, J Silvio, Neupane, Prakash, Mills, Glenn, Sargi, Zoukaa, Seiwert, Tanguy, Grilley-Olson, Juneko, Day, Terry, Gillison, Maura, Wade, James L, Feldman, Lawrence, Jha, Gautam, Kozloff, Mark, O'Leary, Miriam, Worden, Francis P, and Cohen, Ezra EW
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Clinical Research ,Clinical Trials and Supportive Activities ,Dental/Oral and Craniofacial Disease ,Rare Diseases ,Cancer ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Male ,Humans ,Female ,Middle Aged ,Everolimus ,Squamous Cell Carcinoma of Head and Neck ,Prospective Studies ,Carcinoma ,Squamous Cell ,Head and Neck Neoplasms ,Epithelial Cells ,Oncology & Carcinogenesis ,Clinical sciences ,Oncology and carcinogenesis - Abstract
PurposeInvestigate whether adjuvant everolimus, an mTOR inhibitor, improves progression-free survival (PFS) in advanced-stage head and neck squamous cell carcinoma (HNSCC) and provide outcomes related to correlative biological factors associated with disease control.Patients and methodsThis was a prospective, randomized, double-blind phase II trial of patients with advanced-stage HNSCC from 13 institutions who were confirmed disease-free post-definitive therapy and enrolled between December 2010 and March 2015. Patients received adjuvant everolimus or placebo daily (10 mg, oral) for a maximum of 1 year. p16 IHC as a surrogate marker for human papillomavirus infection and whole-exome sequencing were performed. Cox proportional hazard models estimated hazard rates. Log-rank tests evaluated differences in survival. The primary endpoint was PFS. Secondary endpoints and objectives included overall survival (OS) and toxicity assessment.Results52 patients [median (range) age, 58 (37-76) years; 43 men (83%), 9 women (17%)] were randomized to placebo (n = 24) or everolimus (n = 28). PFS favored everolimus, but was not significant [log-rank P = 0.093; HR = 0.44; 95% confidence interval (CI), 0.17-1.17]. There was no difference in OS (P = 0.29; HR = 0.57; 95% CI, 0.20-16.2). Everolimus resulted in significant improvement in PFS for p16-negative patients (n = 31; P = 0.031; HR = 0.26; 95% CI, 0.07-0.97), although subgroup analysis showed no difference for p16-positive patients (n = 21; P = 0.93). Further, PFS was significantly higher in TP53-mutated (TP53mut) patients treated with everolimus compared with placebo (log-rank P = 0.027; HR = 0.24; 95% CI, 0.06-0.95). No treatment difference was seen in patients with TP53 wild-type tumors (P = 0.79).Conclusionsp16-negative and TP53mut patients may benefit from adjuvant treatment with everolimus.
- Published
- 2022
207. Somatostatin analogues in treatment-refractory meningioma: a systematic review with meta-analysis of individual patient data
- Author
-
Jensen, Lasse Rehné, Maier, Andrea Daniela, Lomstein, Atle, Graillon, Thomas, Hrachova, Maya, Bota, Daniela, Ruiz-Patiño, Alejandro, Arrieta, Oscar, Cardona, Andrés Felipe, Rudà, Roberta, Furtner, Julia, Roeckle, Ulrich, Clement, Paul, Preusser, Matthias, Scheie, David, Broholm, Helle, Kristensen, Bjarne Winther, Skjøth-Rasmussen, Jane, Ziebell, Morten, Munch, Tina Nørgaard, Fugleholm, Kåre, Walter, Martin A, Mathiesen, Tiit, and Mirian, Christian
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Brain Disorders ,Cancer ,Neurosciences ,Clinical Research ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Everolimus ,Humans ,Meningeal Neoplasms ,Meningioma ,Prospective Studies ,Receptors ,Somatostatin ,Somatostatin ,Meta-analysis ,Neuro-oncology ,Treatment-refractory ,Progressive ,Neurology & Neurosurgery ,Clinical sciences ,Dentistry - Abstract
Treatment-refractory meningiomas have a dismal prognosis and limited treatment options. Meningiomas express high-densities of somatostatin receptors (SSTR), thus potentially susceptible to antitumorigenic effects of somatostatin analogues (SSA). Evidence for SSA in meningiomas is scarce, and it is unclear if published literature would either (1) support wider use of SSA, if (2) more evidence is desirable, or if (3) available evidence is sufficient to discard SSA. We addressed the need for more evidence with a systematic review and meta-analysis. We performed an individual patient data (IPD) meta-analysis. Main outcomes were toxicity, best radiological response, progression-free survival, and overall survival. We applied multivariable logistic regression models to estimate the effect of SSA on the probability of obtaining radiological disease control. The predictive performance was evaluated using area under the curve and Brier scores. We included 16 studies and compiled IPD from 8/9 of all previous cohorts. Quality of evidence was overall ranked "very low." Stable disease was reported in 58% of patients as best radiological response. Per 100 mg increase in total SSA dosage, the odds ratios for obtaining radiological disease control was 1.42 (1.11 to 1.81, P = 0.005) and 1.44 (1.00 to 2.08, P = 0.05) for patients treated with SSA as monodrug therapy vs SSA in combination with everolimus, respectively. Low quality of evidence impeded exact quantification of treatment efficacy, and the association between response and treatment may represent reverse causality. Yet, the SSA treatment was well tolerated, and beneficial effect cannot be disqualified. A prospective trial without bias from inconsistent study designs is warranted to assess SSA therapy for well-defined meningioma subgroups.
- Published
- 2022
208. A real-world disproportionality analysis of Everolimus: data mining of the public version of FDA adverse event reporting system.
- Author
-
Bin Zhao, Yumei Fu, Shichao Cui, Xiangning Chen, Shu Liu, and Lan Luo
- Subjects
EVEROLIMUS ,DATA mining ,DRUG side effects ,BREAST ,TUBEROUS sclerosis ,DATABASES ,DATA analysis - Abstract
Background: Everolimus is an inhibitor of the mammalian target of rapamycin and is used to treat various tumors. The presented study aimed to evaluate the Everolimus-associated adverse events (AEs) through data mining of the US Food and Drug Administration Adverse Event Reporting System (FAERS). Methods: The AE records were selected by searching the FDA Adverse Event Reporting System database from the first quarter of 2009 to the first quarter of 2022. Potential adverse event signals were mined using the disproportionality analysis, including reporting odds ratio the proportional reporting ratio the Bayesian confidence propagation neural network and the empirical Bayes geometric mean and MedDRA was used to systematically classify the results. Results: A total of 24,575 AE reports of Everolimus were obtained using data from the FAERS database, and Everolimus-induced AEs occurrence targeted 24 system organ classes after conforming to the four algorithms simultaneously. The common significant SOCs were identified, included benign, malignant and unspecified neoplasms, reproductive system and breast disorders, etc. The significant AEs were then mapped to preferred terms such as stomatitis, pneumonitis and impaired insulin secretion, which have emerged in the study usually reported in patients with Everolimus. Of note, unexpected significant AEs, including biliary ischaemia, angiofibroma, and tuberous sclerosis complex were uncovered in the label. Conclusion: This study provided novel insights into the monitoring, surveillance, and management of adverse drug reaction associated with Everolimus. The outcome of serious adverse events and the corresponding detection signals, as well as the unexpected significant adverse events signals are worthy of attention in order to improving clinical medication safety during treatment of Everolimus. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
209. Dosing‐time, feeding, and sex‐dependent variations of everolimus pharmacokinetics in mice.
- Author
-
Ozturk Civelek, Dilek, Ozturk Seyhan, Narin, Akyel, Yasemin Kubra, Gazioglu, Isil, Pala Kara, Zeliha, Orman, Mehmet N., and Okyar, Alper
- Abstract
Background Objectives Method Results Conclusion Everolimus is an oral mammalian target of rapamycin (mTOR) inhibitor used as an immunosuppressant and anticancer. Its pharmacokinetics is highly variable, it has a narrow therapeutic window and shows chronotoxicity with the best time at ZT13 and worst time at ZT1 (ZT; Zeitgeber time, time after light onset) in the preclinical setting.In the present study, we aimed to investigate whether the pharmacokinetics of everolimus vary according to dosing time and whether sex and feeding status interfere with the chronopharmacokinetics.A single dosage of 5 mg/kg everolimus was administered orally to C57BL/6J male and female mice, in fed or fasted states at ZT1‐rest and ZT13‐activity times and blood and tissue samples were collected at 0.5, 1, 2, 4, 12, and 24 h following drug administration. Ileum, liver, plasma, and thymus concentrations of everolimus were determined.Females had a greater ileum AUC0–24h than males when fed (
P = 0.043). Everolimus AUC0–24h in the liver was substantially greater at ZT1 than at ZT13 in a fasted state (P = 0.001). Plasma Cmax, AUC0–24h, and AUCtotal were not statistically significant between the groups (P = 0.098). In one of the target organs of everolimus, the thymus, males had considerably higher amounts at ZT1 than females (P = 0.029).Our findings imply that the pharmacokinetics of everolimus in mice may differ according to dosing time, sex, and feeding. Greater tissue distribution of everolimus at ZT1 may be associated with the worst tolerated time of everolimus. Our research suggests that oral chronomodulated everolimus therapy may be more effective and safer for cancer patients. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
210. Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial.
- Author
-
Gómez Tejeda Zañudo, Jorge, Barroso-Sousa, Romualdo, Jain, Esha, Jin, Qingchun, Li, Tianyu, Buendia-Buendia, Jorge E., Pereslete, Alyssa, Abravanel, Daniel L., Ferreira, Arlindo R., Wrabel, Eileen, Helvie, Karla, Hughes, Melissa E., Partridge, Ann H., Overmoyer, Beth, Lin, Nancy U., Tayob, Nabihah, Tolaney, Sara M., and Wagle, Nikhil
- Subjects
METASTATIC breast cancer ,CETUXIMAB ,CYCLIN-dependent kinase inhibitors ,ESTROGEN receptors ,EVEROLIMUS ,TRANSCRIPTOMES ,PROGRESSION-free survival - Abstract
The landscape of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) resistance is still being elucidated and the optimal subsequent therapy to overcome resistance remains uncertain. Here we present the final results of a phase Ib/IIa, open-label trial (NCT02871791) of exemestane plus everolimus and palbociclib for CDK4/6i-resistant metastatic breast cancer. The primary objective of phase Ib was to evaluate safety and tolerability and determine the maximum tolerated dose/recommended phase II dose (100 mg palbociclib, 5 mg everolimus, 25 mg exemestane). The primary objective of phase IIa was to determine the clinical benefit rate (18.8%, n = 6/32), which did not meet the predefined endpoint (65%). Secondary objectives included pharmacokinetic profiling (phase Ib), objective response rate, disease control rate, duration of response, and progression free survival (phase IIa), and correlative multi-omics analysis to investigate biomarkers of resistance to CDK4/6i. All participants were female. Multi-omics data from the phase IIa patients (n = 24 tumor/17 blood biopsy exomes; n = 27 tumor transcriptomes) showed potential mechanisms of resistance (convergent evolution of HER2 activation, BRAF
V600E ), identified joint genomic/transcriptomic resistance features (ESR1 mutations, high estrogen receptor pathway activity, and a Luminal A/B subtype; ERBB2/BRAF mutations, high RTK/MAPK pathway activity, and a HER2-E subtype), and provided hypothesis-generating results suggesting that mTOR pathway activation correlates with response to the trial's therapy. Our results illustrate how genome and transcriptome sequencing may help better identify patients likely to respond to CDK4/6i therapies. Intrinsic and acquired resistances to CDK4/6 inhibitors have been described in patients with breast cancer. Here the authors report the results from a phase I/II clinical trial of the aromatase inhibitor exemestane plus everolimus (mTOR inhibitor) and palbociclib (CDK4/6i) in patients with metastatic breast cancer, assessing safety, clinical efficacy, as well as genomic and transcriptomic determinants of resistance. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
211. Responses to Medical Treatment in 192 Patients with Pancreatic Neuroendocrine Neoplasms Referred to the Copenhagen Neuroendocrine Tumour Centre in 2000–2020.
- Author
-
Petersen, Sofie Skovlund, Møller, Stine, Slott, Cecilie, Krogh, Jesper, Hansen, Carsten Palnæs, Kjaer, Andreas, Holmager, Pernille, Oturai, Peter, Garbyal, Rajendra Singh, Langer, Seppo W., Knigge, Ulrich, and Andreassen, Mikkel
- Subjects
- *
RADIOISOTOPE therapy , *CANCER treatment , *RESEARCH funding , *TREATMENT effectiveness , *RETROSPECTIVE studies , *DESCRIPTIVE statistics , *CARBOPLATIN , *PANCREATIC tumors , *ETOPOSIDE , *CANCER chemotherapy , *NEUROENDOCRINE tumors , *PROGRESSION-free survival , *CONFIDENCE intervals , *SPECIALTY hospitals , *MEDICAL referrals , *OVERALL survival , *ALGORITHMS , *EVALUATION - Abstract
Simple Summary: Pancreatic neuroendocrine tumors are a rare and heterogenous group of neoplasms. Surgical resection is the only curative option. However, there has been an increase in palliative medical options. The aim of this retrospective study was to investigate responses for the most commonly used medical treatments in 192 patients. The current results support the effectiveness of somatostatin analogues in low-grade tumors and showed that it might also be used in patients with Ki-67 ≥ 10%. Treatment with streptozocin and 5-floururacil as first-line treatment showed good efficacy for G2 disease. Due to good efficacy and generally good tolerability PRRT might be considered as first-line treatment for NET G2. The results confirmed poor prognosis in high-grade tumors treated with carboplatin/etoposide or temozolomide. The current results provide valuable knowledge as current treatment algorithms and sequencing are primarily guided by expert opinions with limited evidence. Background: Given the rarity and heterogeneity of pancreatic neuroendocrine neoplasms (pNEN), treatment algorithms and sequencing are primarily guided by expert opinions with limited evidence. Aim: To investigate overall survival (OS), median progression-free survival (mPFS), and prognostic factors associated with the most common medical treatments for pNEN. Methods: Retrospective single-center study encompassing patients diagnosed and monitored between 2000 and 2020 (n = 192). Results: Median OS was 36 (95% CI: 26–46) months (99 months for grade (G) 1, 62 for G2, 14 for G3, and 10 for neuroendocrine carcinomas). Patients treated with somatostatin analogues (SSA) (n = 59, median Ki-67 9%) had an mPFS of 28 months. Treatment line (HR (first line as reference) 4.1, 95% CI: 1.9–9.1, p ≤ 0.001) emerged as an independent risk factor for time to progression. Patients with a Ki-67 index ≥10% (n = 28) had an mPFS of 27 months. Patients treated with streptozocin/5-fluorouracil (STZ/5FU) (n = 70, first-line treatment n = 68, median Ki-67 10%) had an mPFS of 20 months, with WHO grade serving as an independent risk factor (HR (G1 (n = 8) vs. G2 (n = 57)) 2.8, 95% CI: 1.1–7.2, p-value = 0.031). Median PFS was 21 months for peptide receptor radionuclide therapy (PRRT) (n = 41, first line n = 2, second line n = 29, median Ki-67 8%), 5 months for carboplatin and etoposide (n = 66, first-line treatment n = 60, median Ki-67 80%), and 3 months for temozolomide-based therapy (n = 56, first-line treatment n = 17, median Ki-67 30%). Conclusion: (1) Overall survival was, as expected, highly dependent on grade; (2) median PFS for SSA was around 2.5 years without difference between tumors with Ki-67 above or below 10%; (3) STZ/5FU as first-line treatment exhibited a superior mPFS of 20 months compared to what has historically been reported for targeted treatments; (4) PRRT in G2 pNEN achieved an mPFS similar to first-line chemotherapy; and (5) limited treatment efficacy was observed in high-grade tumors when treated with carboplatin and etoposide or temozolomide. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
212. Case report: Sustained complete remission with all-oral MEPED therapy in a patient with Hodgkin's disease developing resistance to pembrolizumab.
- Author
-
Reuthner, K., Aubele, P., Menhart, K., Rath, P., Harrer, D. C., Herr, W., Hahn, J., Vogelhuber, M., Heudobler, D., Lueke, F., Reichle, A., and Grube, M.
- Subjects
HODGKIN'S disease ,EVEROLIMUS ,NATURAL immunity ,IMMUNE checkpoint inhibitors ,PEMBROLIZUMAB ,HERBICIDE resistance - Abstract
Targeted chemotherapy and immune checkpoint inhibitors (ICPi) have expanded the spectrum of therapies for patients with relapsed/refractory (r/r) Hodgkin's disease and significantly improved the proportion of patients with long-term disease control. However, there is no standardized therapeutic option in case of further progression. Recently, we demonstrated that therapy with MEPED (metronomic chemotherapy, everolimus, pioglitazone, etoricoxib, dexamethasone) is highly effective in patients with r/r Hodgkin's disease. The benefit after pre-treatment with ICPi has not been studied, yet. Here, we report a patient with progressive Hodgkin's disease on Pembrolizumab for the first time who achieved sustained complete remission (CR) after initiation of MEPED therapy. A 57-year-old patient was pre-treated with brentuximab vedotin for relapsed advanced Hodgkin's disease and had received Pembrolizumab for progression from November 2020 to July 2022. Due to further progression, MEPED therapy was started in August 2022 and continued until May 2023. It consisted of a strictly oral daily (28-day cycle) application of low-dose treosulfan 250 mg, everolimus 15 mg, pioglitazone 45 mg, etoricoxib 60 mg, and dexamethasone 0.5 mg. Treatment response was evaluated by F-18 FDG-PET/CT (PET/CT). CR was defined by a negative Deauville score (DS) of 1-3. Already 3 months after starting MEPED, a CR (DS: 3) was confirmed by PET/CT in November 2022. The next follow-up in May 2023 continued to show CR (DS: 3). The therapy was very well tolerated. No hematological or other organ toxicity was observed. However, in May 2023 the patient presented with leg edema and weight gain, most likely due to pioglitazone and the PET/CT revealed suspected everolimus-induced pneumonitis, so MEPED was discontinued and diuretic therapy and treatment with prednisolone was started with gradual dose reduction. This resulted in a rapid complete resolution of the symptoms. The next PET-CT in July 2023 continued to show CR (DS: 3) without evidence of pneumonitis. Currently, therapy with MEPED has not been resumed. In conclusion, we demonstrate for the first time that MEPED therapy is highly effective in a patient with Hodgkin's disease who has been refractory to ICPi. Sustained CR was achieved over 11 months after initiation of MEPED therapy. Further studies on a larger patient cohort should be performed. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
213. Clinicopathological Characteristics of Everolimus-Associated Interstitial Lung Disease: A Single-Center Consecutive Analysis.
- Author
-
Yoshinobu Saito, Yasuhiro Terasaki, Takeru Kashiwada, Toru Tanaka, Hiroyuki Takei, Go Kimura, Yukihiro Kondo, Tetsuro Kawagoe, Akira Matsushita, Rintaro Noro, Yuji Minegishi, Koichiro Kamio, Masahiro Seike, and Akihiko Gemma
- Abstract
The article focuses on investigating the clinicopathological characteristics of interstitial lung disease (ILD) associated with everolimus, an antineoplastic drug. It aims to elucidate the features of everolimus-associated ILD, including its severity, radiological findings, biomarker changes, and lung histopathological features. It highlights the importance of early detection and careful monitoring strategies for ILD in patients undergoing everolimus therapy.
- Published
- 2024
- Full Text
- View/download PDF
214. mTor‐inhibition within the first days after pediatric heart transplantation is a potentially safe option to prevent cardiac allograft vasculopathy.
- Author
-
Kreienbaum, Hannah, Stiller, Brigitte, Kubicki, Rouven, Bobrowski, Alexej, Kroll, Johannes, and Fleck, Thilo
- Subjects
- *
EVEROLIMUS , *HOMOGRAFTS , *HEART transplantation , *ARTIFICIAL blood circulation , *HEART transplant recipients , *VASCULAR diseases , *CHRONIC kidney failure - Abstract
Background: Immunosuppression after heart transplantation (HTX) with mammalian target of rapamycin (mTOR) inhibitors serves as a prophylaxis against rejection and to treat coronary vascular injury. However, there is little data on the early, preventive use of everolimus after pediatric HTX. Methods: Retrospective study of 61 pediatric HTX patients (48 cardiomyopathy and 13 congenital heart disease), 28 females, median age 10.1 (range 0.1–17.9) years transplanted between 2008 and 2020. We analyzed survival, rejection, renal function, occurrence of lymphoproliferative disorder, and allograft vasculopathy together with adverse effects of early everolimus therapy combined with low‐dose calcineurin inhibitors. Results: Everolimus therapy was started at a median 3.9 (1–14) days after HTX. Median follow‐up was 4.3 (range 0.5–11.8) years, cumulative 184 patient years. The estimated 1‐ and 5‐year survival probability was 89% (CI 82%:98%) and 87% (CI 78%:97%). Four patients developed rejection (6.6%) (maximum 2R ISHLT criteria). No patient suffered from chronic renal failure. Three patients (4.9%) developed post‐transplant lymphoproliferative disorder. Five patients suffered relevant wound‐healing disorders after transplantation, four of them carrying relevant risk factors before HTX (mechanical circulatory support (n = 3), delayed chest closure after HTX (n = 3)). No recipient developed cardiac allograft vasculopathy. Conclusion: Initiating everolimus within the first 14 days after HTX seems to be well tolerated, enabling a low incidence of rejection, post‐transplant lymphoproliferative disorders, renal failure, and reveals no evidence of cardiac allograft vasculopathy as well as good overall survival in pediatric heart transplant recipients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
215. Treatment of tuberous sclerosis complex manifestations in children with mTOR inhibitors.
- Author
-
Yeşil, Şule, Kurucu, Burçak, Hamamcı, Melda Berber, Yılmaz, Şükriye, and Şahin, Gürses
- Subjects
- *
TUBEROUS sclerosis , *EVEROLIMUS , *MTOR inhibitors , *HAMARTOMA , *PATHOLOGY , *ANTICONVULSANTS , *PEDIATRIC oncology - Abstract
Purpose: Tuberous sclerosis complex (TSC) is a rare autosomal dominant genetic disorder that affects multiple organ systems. Mutations in the TSC1 and TSC2 genes result in the constitutive hyperactivation of the mammalian target of rapamycin (mTOR) pathway, contributing to the growth of benign tumors or hamartomas in various organs. Due to the implication of mTOR pathway dysregulation in the disease pathology, increasing evidence supports the use of mTOR inhibitors for treating multiple manifestations of TSC. Methods: In this study, we conducted a retrospective analysis of clinical findings and treatment data from 38 patients diagnosed with tuberous sclerosis who were followed up in the Pediatric Oncology Clinic between 2010 and 2020. We collected information on patients' ages, genders, affected sites, familial history, imaging findings, presence of tumors, and treatments. Results: Among the patients, nine individuals with TSC manifestations were treated with mTOR inhibitors. Specifically, everolimus was successfully administered to five patients with inborn cardiac rhabdomyoma causing hemodynamic impairment. In addition, two patients with refractory seizures received everolimus in combination with anti-epileptic drugs. A patient with renal angiomyolipomas larger than 3 cm was treated with everolimus, while a patient with extensive facial angiofibroma received topical sirolimus. All patients tolerated the mTOR inhibitors well, and the side effects were deemed acceptable. Conclusion: The utilization of mTOR inhibition in TSC is expected to become more prevalent in clinical practice, as current research is anticipated to provide a better understanding of the therapeutic roles of these treatments in TSC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
216. An updated meta-analysis of effectiveness and safety of mTOR inhibitors in the management of tuberous sclerosis complex patients.
- Author
-
Liu, Mengling, Ye, Jiayou, and You, Xiaoling
- Subjects
- *
TUBEROUS sclerosis , *EVEROLIMUS , *EPILEPSY , *MTOR inhibitors , *ONLINE databases , *TREATMENT effectiveness - Abstract
Purpose: Tuberculous sclerosis complex (TSC) is an autosomal dominant multi-system disease. In TSC patients, the inhibition of mTOR pathway is weakened, which leads to the uncontrolled proliferation of normal resting cells. Therefore, mTOR inhibitors have many therapeutic potentials in the treatment of TSC. However, there is no consensus on the safety and efficacy of mTOR inhibitors so far. This article aimed to present new evidence for the efficacy and safety of mTOR inhibitors in the treatment of TSC by evaluating published clinical trials. Methods: A systemic search of online databases, such as Cochrane Library, Embase, PubMed, and the US National Institutes of Health Clinical Trials Registry, was conducted. The researchers selected studies that met the following entry criteria: randomized, double-blinded or single-blinded, placebo-controlled, parallel-group studies with active and control arms receiving rapamycin or everolimus and matched placebo, respectively. The meta-analysis included seven studies. Tumor response or epilepsy seizure frequency response rates were considered efficacy outcomes. Results: In seven studies involving 877 patients, using of mTOR inhibitors therapy showed an improvement in both tumor response and seizure frequency outcomes in TSC. In combination of AML (angiomyolipomas), SEGA (subependymal giant cell astrocytoma), epilepsy, and facial angiofibroma subjects, the RR is 3.01 (95% CI 2.03 to 4.45, p = 0.000) with observed heterogeneity (I-squared = 55.4%). The main side effect of mTOR inhibitors was stomatitis. Conclusion: The updated meta-analysis suggests that the use of mTOR inhibitors is an effective therapy for patients with TSC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
217. Efficacy of Everolimus Combined with 177Lu-Dotatate in the Treatment of Neuroendocrine Tumors.
- Author
-
Aljubran, Ali, Badran, Ahmed, Alrowaily, Mohamed, Raef, Hussein, Alzahrani, Ahmed M., Almuhaideb, Ahmed, Almanea, Hadeel, El-Dali, Abdelmoneim, Tuli, Mahmoud, and Bazarbashi, Shouki
- Subjects
- *
THERAPEUTIC use of antineoplastic agents , *STOMATITIS , *PATIENT safety , *CLINICAL trials , *TUMOR grading , *NEUROENDOCRINE tumors , *DRUG efficacy , *EVEROLIMUS , *PROGRESSION-free survival , *STROKE , *NAUSEA , *PHARMACODYNAMICS , *EVALUATION - Abstract
Background: Both everolimus and peptide receptor radionuclide therapy (PRRT) are approved as monotherapies for advanced neuroendocrine tumors (NETs). Research in animal models showed synergism between the two treatment modalities. This study aimed to evaluate the safety and efficacy of combining everolimus and PRRT in the treatment of unresectable NETs. Methods: Adult patients (≥18 years) with progressing and unresectable histologically confirmed grade 1-2 NETs of all origins were enrolled. Everolimus was started at a 5 mg daily dose and was increased after the initial three patients to 10 mg daily. Patients were treated concurrently with 177Lu-DOTATATE at an 8-week interval, with planned four cycles. Safety was the primary endpoint, with response rate and progression-free survival (PFS) being secondary. Results: Eleven patients were enrolled. The trial was terminated early for poor accrual. The median age was 51 years (18-64), and 4 were males. The median number of cycles of 177Lu-DOTATATE was 3, and the median cumulative dose was 300 mCi. The most frequent grade 1-2 toxicities were stomatitis (90.9%) and nausea (72.7%). Less frequent were fatigue (63.6%), anorexia, diarrhea, and skin changes (each at a 36.4% rate). Grade 3 toxicities occurred in 36% (fatigue, infection, pneumonitis, neutropenia, and stroke). No patient developed grade 4 toxicity. Treatment was stopped because of progression in three patients, and toxicity in another three patients, in addition, in four patients due to therapy interruption and in one patient who developed stroke. One patient achieved partial response, and nine had stable disease. One patient developed disease progression. At a median follow-up of 18.9 months, three died and one was lost to follow-up. The median PFS was 23.3 months. Conclusions: The combination of everolimus at a dose of 10 mg daily and 177Lu-DOTATATE appears not to be feasible. A larger trial at a lower dose of everolimus is warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
218. مقایسه اثر بخشی و ایمنی پروتکل استفاده Denovo از Everolimus با دوز پایین سیکلوسپورین در برابر پروتکل با دوز استاندارد سیکلوسپورین و Cellcept بر پیشگیری از ایجاد عفونت CMV و BK virus و میزان بقای شش ماه و یکساله پیوند در گیرندگان پیوند کلیه.
- Author
-
نوشین دلیلی, فاطمه پوررضاقلی, مریم السادات موس, مروارید علی نژاد, رضا اسدزاده, صدرا اشرفی, and شيوا سماوات
- Subjects
ADRENOCORTICAL hormones ,KIDNEY transplantation ,PATIENT safety ,CYCLOSPORINE ,MYCOPHENOLIC acid ,CYTOMEGALOVIRUS diseases ,HUMAN beings ,STATISTICAL sampling ,RANDOMIZED controlled trials ,DOSE-effect relationship in pharmacology ,GRAFT rejection ,EVEROLIMUS ,KIDNEYS ,THERAPEUTICS - Abstract
Introduction: Although many years have passed since the first successful kidney transplantation, there are still numerous questions about the best immunosuppression regimen for these patients. Various studies have demonstrated that long-term use of calcineurin inhibitors can be associated with reversible changes accompanied by irreversible damage to all kidney compartments, leading to both acute and chronic nephrotoxicity. Nowadays, the goal is to optimize available immunosuppressive regimens and reduce the calcineurin inhibitor dose as much as possible while protecting the transplanted kidney from rejection. The present study aimed to compare renal function, Cytomegalovirus infection, BK nephropathy rate, and biopsy-proven acute rejection in two regimens: an everolimus plus reduced calcineurin inhibitor based regimen versus a standard dose calcineurin-inhibitor protocol with mycophenolic acid. Material & Methods: This was a 12-month, open-label, randomized study of 60 Iranian kidney transplant recipients (aged 18-65). The first group received cyclosporine at a dose of 3.5 mg per kilogram of body weight together with everolimus 0.75 mg twice a day, along with corticosteroids, and the second group received cyclosporine at a dose of 6 mg per kilogram of body weight along with mycophenolic acid 1 gram twice a day, along with corticosteroids. All patients received thymoglobulin induction. Results: Renal function based on glomerular filtration rate in two groups 6 and 12 months after transplantation did not show a statistically significant difference. Furthermore, there was no difference between the two groups regarding the incidence of transplant rejection, while the rate of cytomegalovirus and BK infection within the first year after transplantation was lower in the group that received everolimus. Discussion & Conclusion: The present study suggested non-inferiority and overall safety of de novo everolimus-based regimen in Iranian kidney transplant recipients with preserved renal function and significantly lower viral infections without increasing the risk of acute rejection in the first post-operation year, which could impact long-term outcomes and offer renal benefits versus the standard calcineurin inhibitor based regimens. [ABSTRACT FROM AUTHOR]
- Published
- 2024
219. Different drugs in drug-eluting stents for peripheral artery disease: a systematic evaluation and Bayesian meta-analysis.
- Author
-
Chen, Keqin, Xu, Lei, and Liu, Xiehong
- Abstract
Drug-eluting stents (DESs) have become the first-line treatment for symptomatic peripheral arterial disease (PAD). Currently, there are many types of DESs on the market. The same type of DESs has different concentrations, and various drugs in them show uneven efficacy. The selection of DESs remains controversial. This study was aimed at comparing the long-term real-world outcomes of different DESs in the treatment of peripheral arterial occlusive disease (PAOD). The databases including Cochrane Library, Embase, and PubMed were searched with a time frame until March 25, 2023. The primary patency (PP) and target lesion revascularization (TLR) at 6 months were used as the primary endpoints. A total of 32 studies (5467 patients) were eligible. At the six-month follow-up, DES-Evero 1 ug/mm2 ranked first in terms of PP, with a significant difference from BMSs (RR [95% CI] = 1.6). DES-Siro 0.9 ug/mm2, DES-Siro 1.4 ug/mm2, DES-Siro 1.95 ug/mm2, DES-PTX 0.167 ug/mm2, DES-PTX 1 ug/mm2 and covered stents (CSs) showed significantly better PPs than BMSs. In terms of TLR, DES-Siro 0.9 ug/mm2 (0.31) ranked first, and DES-Evero 1 ug/mm2 ranked last. Among the treatment modalities for PAD, different DESs showed overall encouraging results in improving PP and TLR compared with BMSs. DES-Evero 1 ug/mm2 showed the best PP, but it had the highest reintervention rate at 6 months. Sirolimus-eluting stents were not always more effective with higher concentrations of sirolimus. Among various DESs, sirolimus-eluting stents and everolimus-eluting stents were superior to paclitaxel-eluting stents. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
220. Clear Cell Renal Cell Carcinoma: A Test Bench for Investigating Tumor Complexity.
- Author
-
Manini, Claudia, López-Fernández, Estíbaliz, Larrinaga, Gorka, and López, José I.
- Subjects
- *
RENAL cell carcinoma , *BIOMARKERS , *IMMUNE checkpoint inhibitors , *PROTEIN-tyrosine kinase inhibitors , *KIDNEY tumors , *EVEROLIMUS , *IMMUNOTHERAPY - Published
- 2024
- Full Text
- View/download PDF
221. A Confusing Collapse: Case of an Intracranial Mass Mimicker in a Cardiac Transplant Recipient.
- Author
-
Lai, Vivien Wai Yun, Griffin, David, Lau, Jillian, McLean, Catriona, Chang, Christina, Bigwood, Shalini, Hare, James, and Morrissey, Orla
- Subjects
- *
ENCEPHALITIS diagnosis , *DIFFERENTIAL diagnosis , *PATIENTS , *TRANSPLANTATION of organs, tissues, etc. , *DIAGNOSTIC imaging , *COMPUTED tomography , *GANCICLOVIR , *CYCLOSPORINE , *MYCOPHENOLIC acid , *MAGNETIC resonance imaging , *IMMUNOENZYME technique , *FEVER , *ELECTROCARDIOGRAPHY , *INTRAVENOUS therapy , *EPSTEIN-Barr virus , *HEART transplantation , *VALGANCICLOVIR , *VIREMIA , *EVEROLIMUS , *ANTIBIOTIC prophylaxis , *DISEASE relapse , *ACCIDENTAL falls , *HEAD injuries , *CONTRAST media ,BRAIN tumor diagnosis - Abstract
The article presents a case study of a 56-year-old cardiac transplant recipient experiencing a collapse, revealing an intracranial mass mimicker, later diagnosed as Epstein-Barr virus (EBV) encephalitis. Topics discussed include the clinical presentation, diagnostic challenges, and treatment approach for EBV encephalitis in immunocompromised patients.
- Published
- 2024
- Full Text
- View/download PDF
222. Concomitant inhibition of PI3K/mTOR signaling pathways boosts antiproliferative effects of lanreotide in bronchopulmonary neuroendocrine tumor cells.
- Author
-
von Hessert-Vaudoncourt, Claus, Lelek, Sara, Geisler, Christina, Hartung, Teresa, Bröker, Vanessa, Briest, Franziska, Mochmann, Liliana, Jost-Brinkmann, Fabian, Sedding, Dagmar, Benecke, Joana, Freitag, Helma, Wolfshöfer, Sebastian, Lammert, Hedwig, Nölting, Svenja, Hummel, Michael, Schrader, Jörg, and Grabowski, Patricia
- Subjects
NEUROENDOCRINE tumors ,NEUROENDOCRINE cells ,SOMATOSTATIN receptors ,CELLULAR signal transduction ,PHOSPHATIDYLINOSITOL 3-kinases ,MITOGENS - Abstract
Introduction: Somatostatin analogues (SSAs) are commonly used in the treatment of hormone hypersecretion in neuroendocrine tumors (NETs), however the extent to which they inhibit proliferation is much discussed. Objective: We studied the antiproliferative effects of novel SSA lanreotide in bronchopulmonary NETs (BP-NETs). We focused on assessing whether pretreating cells with inhibitors for phosphatidylinositol 3-kinase (PI3K) and mammalian target for rapamycin (mTOR) could enhance the antiproliferative effects of lanreotide. Methods: BP-NET cell lines NCI-H720 and NCI-H727 were treated with PI3K inhibitor BYL719 (alpelisib), mTOR inhibitor everolimus and SSA lanreotide to determine the effect on NET differentiation markers, cell survival, proliferation and alterations in cancer-associated pathways. NT-3 cells, previously reported to express somatostatin receptors (SSTRs) natively, were used as control for SSTR expression. Results: SSTR2 was upregulated in NCI-H720 and NT-3 cells upon treatment with BYL719. Additionally, combination treatment consisting of BYL719 and everolimus plus lanreotide tested in NCI-H720 and NCI-H727 led to diminished cell proliferation in a dose-dependent manner. Production of proteins activating cell death mechanisms was also induced. Notably, a multiplexed gene expression analysis performed on NCI-H720 revealed that BYL719 plus lanreotide had a stronger effect on the downregulation of mitogens than lanreotide alone. Discussion/Conclusion: We report a widespread analysis of changes in BP-NET cell lines at the genetic/protein expression level in response to combination of lanreotide with pretreatment consisting of BYL719 and everolimus. Interestingly, SSTR expression reinduction could be exploited in therapeutic and diagnostic applications. The overall results of this study support the evaluation of combination-based therapies using lanreotide in preclinical studies to further increase its antiproliferative effect and ultimately facilitate its use in highgrade tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
223. PBRM1 loss is associated with increased sensitivity to MCL1 and CDK9 inhibition in clear cell renal cancer.
- Author
-
Fultang, Norman, Schwab, Ashley M., McAneny-Droz, Sophia, Grego, Alexander, Rodgers, Stephanie, Torres, Brian Vidal, Heiser, Diane, Scherle, Peggy, and Bhagwat, Neha
- Subjects
RENAL cancer ,DRUG resistance in cancer cells ,EVEROLIMUS ,CANCER cells ,SUNITINIB ,TUMOR growth - Abstract
MCL1 is a member of the BCL2 family of apoptosis regulators, which play a critical role in promoting cancer survival and drug resistance. We previously described PRT1419, a potent, MCL1 inhibitor with anti-tumor efficacy in various solid and hematologic malignancies. To identify novel biomarkers that predict sensitivity to MCL1 inhibition, we conducted a gene essentiality analysis using gene dependency data generated from CRISPR/Cas9 cell viability screens. We observed that clear cell renal cancer (ccRCC) cell lines with damaging PBRM1 mutations displayed a strong dependency on MCL1. PBRM1 (BAF180), is a chromatin-targeting subunit of mammalian pBAF complexes. PBRM1 is frequently altered in various cancers particularly ccRCC with ~40% of tumors harboring damaging PBRM1 alterations. We observed potent inhibition of tumor growth and induction of apoptosis by PRT1419 in various preclinical models of PBRM1-mutant ccRCC but not PBRM1-WT. Depletion of PBRM1 in PBRM1-WT ccRCC cell lines induced sensitivity to PRT1419. Mechanistically, PBRM1 depletion coincided with increased expression of pro-apoptotic factors, priming cells for caspase-mediated apoptosis following MCL1 inhibition. Increased MCL1 activity has been described as a resistance mechanism to Sunitinib and Everolimus, two approved agents for ccRCC. PRT1419 synergized with both agents to potently inhibit tumor growth in PBRM1-loss ccRCC. PRT2527, a potent CDK9 inhibitor which depletes MCL1, was similarly efficacious in monotherapy and in combination with Sunitinib in PBRM1-loss cells. Taken together, these findings suggest PBRM1 loss is associated with MCL1i sensitivity in ccRCC and provide rationale for the evaluation of PRT1419 and PRT2527 for the treatment for PBRM1-deficient ccRCC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
224. Efficacy of Immune Checkpoint Inhibitors vs. Tyrosine Kinase Inhibitors/Everolimus in Adjuvant Renal Cell Carcinoma: Indirect Comparison of Disease-Free Survival.
- Author
-
Ossato, Andrea, Gasperoni, Lorenzo, Del Bono, Luna, Messori, Andrea, and Damuzzo, Vera
- Subjects
- *
RENAL cell carcinoma , *DRUG efficacy , *IMMUNE checkpoint inhibitors , *METASTASIS , *ANTINEOPLASTIC agents , *PROTEIN-tyrosine kinase inhibitors , *COMPARATIVE studies , *EVEROLIMUS , *KAPLAN-Meier estimator , *DESCRIPTIVE statistics , *PROGRESSION-free survival , *OVERALL survival , *EVALUATION - Abstract
Simple Summary: The proven efficacy of mTOR inhibitor (mTORI), tyrosine kinase inhibitor (TKI) or immune checkpoint inhibitor (ICI) therapies in metastatic renal cell carcinoma (RCC) suggests that these agents should be investigated as adjuvant therapy with the aim of eliminating undetectable microscopic residual disease after curative resection. Our study aimed to compare the efficacy of these treatments using an innovative method that reconstructs individual patient data from Kaplan–Meier (KM) curves. Nine phase III trials describing different treatment options for adjuvant RCC were selected. Individual patient data were reconstructed from KM curves of disease-free survival (DFS) using the IPDfromKM method. DFS was then compared between the combination treatments and the control arm (placebo). The results were summarized as multi-treatment KM curves. Standard statistical tests were used, including the hazard ratio for superiority and the likelihood ratio test for heterogeneity. In the population of these nine trials, our study showed that two ICIs (nivolumab plus ipilimumab and pembrolizumab) and one TKI (sunitinib) were superior to the placebo, whereas the remaining TKIs and mTORIs were not. As we assessed DFS as the primary endpoint for the adjuvant comparison, the overall survival benefit remains unknown. This novel approach to studying survival has allowed us to make all of the indirect head-to-head comparisons between these agents in a context where no "real" comparative trials have been conducted. Background: The proven efficacy of mTOR inhibitors (mTORIs), tyrosine kinase inhibitors (TKIs) or immune checkpoint inhibitors (ICIs) in metastatic renal cell carcinoma (RCC) suggests that these agents should be investigated as adjuvant therapy with the aim of eliminating undetectable microscopic residual disease after curative resection. The aim of our study was to compare the efficacy of these treatments using an innovative method of reconstructing individual patient data. Methods: Nine phase III trials describing adjuvant RCC treatments were selected. The IPDfromKM method was used to reconstruct individual patient data from Kaplan–Meier (KM) curves. The combination treatments were compared with the control arm (placebo) for disease-free survival (DFS). Multi-treatment KM curves were used to summarize the results. Standard statistical tests were performed. These included hazard ratio and likelihood ratio tests for heterogeneity. Results: In the overall population, the study showed that two ICIs (nivolumab plus ipilimumab and pembrolizumab) and one TKI (sunitinib) were superior to the placebo, whereas both TKIs and mTORIs were inferior. As we assessed DFS as the primary endpoint for the adjuvant comparison, the overall survival benefit remains unknown. Conclusions: This novel approach to investigating survival has allowed us to conduct all indirect head-to-head comparisons between these agents in a context where no "real" comparative trials have been conducted. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
225. In Vitro Sensitivity of Neuroendocrine Neoplasms to an Armed Oncolytic Measles Vaccine Virus.
- Author
-
Scheicher, Nikolai V., Berchtold, Susanne, Beil, Julia, Smirnow, Irina, Schenk, Andrea, and Lauer, Ulrich M.
- Subjects
- *
IN vitro studies , *CLINICAL trials , *HETEROCYCLIC compounds , *ANTINEOPLASTIC agents , *NEUROENDOCRINE tumors , *EVEROLIMUS , *DESCRIPTIVE statistics , *RESEARCH funding , *MEASLES vaccines , *CELL lines , *ONCOLYTIC virotherapy , *PHARMACODYNAMICS - Abstract
Simple Summary: Although a variety of treatment options are available for neuroendocrine neoplasms (NENs), amongst others, including systemic chemotherapy, radiation with the radiosensitizing CAP/TEM regime, the mTOR inhibitor everolimus, the multi-kinase inhibitor sunitinib, or immune checkpoint inhibitors, treatment efficacy is limited and the prognosis for this disease is still very poor. In this situation, oncolytic virotherapy with efficacy-enhanced second-generation measles vaccine virus MeV-SCD could be a promising therapeutic option and may open up a new platform for NEN patients by providing further combination therapies with existing therapeutics such as everolimus or immune checkpoint inhibitors. Neuroendocrine neoplasms represent a heterogenous group of rare tumors whose current therapeutic options show only limited efficacy. Oncolytic viruses exert their mode of action through (onco-)lysis of infected tumor cells and the induction of a systemic antitumoral immune response in a virus-induced inflammatory micromilieu. Here, we investigated the potential of our well-established second-generation suicide-gene armed oncolytic measles vaccine virus (MeV-SCD) in five human NEN cell lines. First, (i) expression of the MeV receptor CD46 and (ii) its correlation with primary infection rates were analyzed. Next, (iii) promising combination partners for MeV-SCD were tested by employing either the prodrug 5-fluorocytosine, which is converted into the chemotherapeutic compound 5-fluorouracil, or the mTOR-inhibitor everolimus. As a result, MeV-SCD was found to kill all NEN tumor cell lines efficiently in a dose-dependent manner. This oncolytic effect was further enhanced by exploiting the prodrug-converting system, which was found to be highly instrumental in overcoming the partial resistance found in a single NEN cell line. Furthermore, viral replication was unaffected by everolimus, which is a basic requirement for combined use in NEN patients. These data suggest that MeV-SCD has profound potential for patients with NEN, thus paving the way for early clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
226. Everolimus inhibits hepatoblastoma by inducing autophagy‐dependent ferroptosis.
- Author
-
Huang, Haijin, Yan, Jinlong, Xu, Xianyun, Feng, Yanping, Liu, Haijin, Liu, Jianping, Xie, Mingfeng, Chen, Leifeng, Xiang, Deng, Peng, Wei, Zeng, Linshan, Zeng, Yong, Chen, Feng, Zhang, Shouhua, and Liu, Qian
- Subjects
- *
GLUTATHIONE peroxidase , *EVEROLIMUS , *HEPATOBLASTOMA , *MICROTUBULE-associated proteins , *REACTIVE oxygen species , *TRANSMISSION electron microscopy - Abstract
Everolimus, a known inhibitor of the mammalian target of rapamycin (mTOR), has shown uncertain efficacy in treating hepatoblastoma. This study delves into the potential anti‐hepatoblastoma properties of everolimus and its intricate relationship with autophagy and ferroptosis, both in vitro and in vivo. In vivo, tumor tissue from hepatoblastoma patient and human hepatoblastoma cell line HuH‐6 were xenografted into nude mice to establish xenograft models for observing the effect of everolimus on tumor growth. In vitro, HuH‐6 cells were cultured to evaluate the anti‐hepatoblastoma activity of everolimus. Transmission electron microscopy and microtubule‐associated proteins 1 light chain 3 (LC3), beclin 1, and p62 protein expressions were employed to investigate autophagy. Additionally, indicators of cell apoptosis, reactive oxygen species (ROS) and proteins associated with ferroptosis were measured to evaluate ferroptosis. The results demonstrate that everolimus treatment effectively induced the formation of autophagosomes in hepatoblastoma cells, upregulated the LC3II/I ratio and beclin 1 expression, and downregulated p62 expression, indicating an enhanced autophagy level both in vitro and in vivo. Furthermore, everolimus treatment induced cell apoptosis, increased ROS level, elevated concentrations of malondialdehyde, 4‐hydroxynonenal, and iron content, while reducing the ratio of glutathione/oxidized glutathione, and downregulating the protein expression of glutathione peroxidase 4 and solute carrier family 7 member 11, suggesting its ability to induce ferroptosis in hepatoblastoma cells. Importantly, the induction of ferroptosis by everolimus was significantly reversed in the presence of autophinib, an autophagy inhibitor, indicating the autophagy‐dependent of everolimus‐induced ferroptosis. Taken together, these findings suggest that everolimus holds promise as an effective anti‐hepatoblastoma drug, with its mechanism of action potentially involving the induction of autophagy‐dependent ferroptosis in hepatoblastoma cells. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
227. Case report: ex vivo tumor organoid drug testing identifies therapeutic options for stage IV ovarian carcinoma.
- Author
-
Al-Aloosi, Marwah, Prechtl, Amanda M., Chatterjee, Payel, Bernard, Brady, Kemp, Christopher J., Rosati, Rachele, Diaz, Robert L., Appleyard, Lauren R., Pereira, Shalini, Rajewski, Alex, McDonald, Amber, Gordon, Eva J., and Grandori, Carla
- Subjects
OVARIAN cancer ,DRUG use testing ,PATIENT experience ,FULVESTRANT ,HOSPICE care ,INDIVIDUALIZED medicine - Abstract
Patients presenting with stage 4 ovarian carcinoma, including low-grade serous disease, have a poor prognosis. Although platinum-based therapies can offer some response, these therapies are associated with many side effects, and treatment resistance often develops. Toxic side effects along with disease progression render patients unable to receive additional lines of treatment and limit their options to hospice or palliative care. In this case report, we describe a patient with an unusual case of metastatic low-grade serous ovarian cancer with some features of high-grade disease who had received four previous lines of treatment and was suffering from atelectasis, pulmonary embolism, and hydronephrosis. A CLIA-certified drug sensitivity assay of an organoid culture derived from the patient's tumor (PARIS® test) identified several therapeutic options, including the combination of fulvestrant with everolimus. On this treatment regimen, the patient experienced 7 months of stable disease and survived nearly 11 months before succumbing to her disease. This case emphasizes the clinical utility of ex vivo drug testing as a new functional precision medicine approach to identify, in real-time, personalized treatment options for patients, especially those who are not benefiting from standard of care treatments. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
228. Co-release of cytokines after drug-eluting stent implantation in acute myocardial infarction patients with PCI.
- Author
-
Wan, Minying, Hu, Kun, Lu, Yi, Wang, Cheng, Mao, Bin, Yang, Qing, Zheng, Zhenzhong, Wu, Hao, Luo, Yihong, and Maiti, Amit K.
- Subjects
- *
MYOCARDIAL infarction , *PERCUTANEOUS coronary intervention , *PRASUGREL , *CORONARY artery disease , *EVEROLIMUS , *CYTOKINES , *PLATELET aggregation inhibitors , *BRUGADA syndrome - Abstract
Acute Myocardial Infarction (AMI) after Percutaneous Coronary Intervention (PCI) often requires stent implantation leading to cardiovascular injury and cytokine release. Stent implantation induces cytokines production including TNFα, Hs-CRP, IL-1ß, IL2 receptor, IL6, IL8, and IL10, but their co-release is not extensively established. In 311 PCI patients with Drug-Eluting Stent (DES) implantation, we statistically evaluate the correlation of these cytokines release in various clinical conditions, stent numbers, and medications. We observed that TNFα is moderately correlated with IL-1ß (r2 = 0.59, p = 0.001) in diabetic PCI patients. Similarly, in NSTEMI (Non-ST Segment Elevation) patients, TNFα is strongly correlated with both IL-1ß (r2 = 0.97, p = 0.001) and IL8 (r2 = 0.82, p = 0.001). In CAD (Coronary Artery Disease)-diagnosed patients TNFα is highly correlated (r2 = 0.84, p = 0.0001) with IL8 release but not with IL-1ß. In patients with an increased number of stents, Hs-CRP is significantly coupled with IL8 > 5 pg/ml (t-statistic = 4.5, p < 0.0001). Inflammatory suppressor drugs are correlated as TNFα and IL8 are better suppressed by Metoprolol 23.75 (r2 = 0.58, p < 0.0001) than by Metoprolol 11.87 (r2 = 0.80, p = 0.5306). Increased TNFα and IL-1ß are better suppressed by the antiplatelet drug Brilinta (r2 = 0.30, p < 0.0001) but not with Clopidogrel (r2 = 0.87, p < 0.0001). ACI/ARB Valsartan 80 (r2 = 0.43, p = 0.0011) should be preferred over Benazepril 5.0 (r2 = 0.9291, p < 0.0001) or Olmesartan (r2 = 0.90, p = 0.0001). Thus, the co-release of IL-1ß, IL8 with TNFα, or only IL8 with TNFα could be a better predictor for the outcome of stent implantation in NSTEMI and CAD-diagnosed AMI patients respectively. Cytokine suppressive medications should be chosen carefully to inhibit further cardiovascular damage. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
229. Clinical Outcome after Everolimus-Eluting Stent Implantation for Small Vessel Coronary Artery Disease: XIENCE Asia Small Vessel Study.
- Author
-
Doo Sun Sim, Dae Young Hyun, Young Joon Hong, Ju Han Kim, Youngkeun Ahn, Myung Ho Jeong, Sang Rok Lee, Jei Keon Chae, Keun Ho Park, Young Youp Koh, Kyeong Ho Yun, Seok Kyu Oh, Seung Jae Joo, Sun Ho Hwang, Jong Pil Park, Jay Young Rhew, Su Hyun Kim, Jang Hyun Cho, Seung Uk Lee, and Dong Goo Kang
- Subjects
- *
MYOCARDIAL infarction , *CORONARY artery disease , *CORONARY arteries , *EAST Asians , *INTRAVASCULAR ultrasonography , *KOREANS - Abstract
There are limited data on outcomes after implantation of everolimus-eluting stents (EES) in East Asian patients with small vessel coronary lesions. A total of 1,600 patients treated with XIENCE EES (Abbott Vascular, CA, USA) were divided into the small vessel group treated with one =2.5 mm stent (n=119) and the non-small vessel group treated with one =2.75 mm stent (n=933). The primary end point was a patient-oriented composite outcome (POCO), a composite of all-cause death, myocardial infarction (MI), and any repeat revascularization at 12 months. The key secondary end point was a device-oriented composite outcome (DOCO), a composite of cardiovascular death, target-vessel MI, and target lesion revascularization at 12 months. The small vessel group was more often female, hypertensive, less likely to present with ST-elevation MI, and more often treated for the left circumflex artery, whereas the non-small vessel group more often had type B2/C lesions, underwent intravascular ultrasound, and received unfractionated heparin. In the propensity matched cohort, the mean stent diameter was 2.5±0.0 mm and 3.1±0.4 mm in the small and non-small vessel groups, respectively. Propensity-adjusted POCO at 12 months was 6.0% in the small vessel group and 4.3% in the non-small vessel group (p=0.558). There was no significant difference in DOCO at 12 months (small vessel group: 4.3% and non-small vessel group: 1.7%, p=0.270). Outcomes of XIENCE EES for small vessel disease were comparable to those for non-small vessel disease at 12-month clinical follow-up in real-world Korean patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
230. A New Hypothesis Describing the Pathogenesis of Oral Mucosal Injury Associated with the Mammalian Target of Rapamycin (mTOR) Inhibitors.
- Author
-
Sonis, Stephen T. and Villa, Alessandro
- Subjects
- *
CANKER sores , *MTOR inhibitors , *ORAL diseases , *HYPOTHESIS , *ORAL mucosa - Abstract
Simple Summary: The mammalian/mechanistic target of the rapamycin (mTOR) pathway is made up of many components that have far-reaching biological consequences, such as cell division, growth, and metabolism. The results of experiments performed years ago showed that inhibitors of the mTOR pathway have a negative effect on tumor cells, which sparked interest in the development of a class of drugs called mTOR inhibitors as anti-cancer therapies. mTOR inhibitors are now part of oncologists' armamentarium for various types of cancers, but patients who use these drugs are at a high risk of developing painful mouth sores. In this paper, we provide a hypothesis as to why these sores develop, how their development compares to other common mouth sores such as canker sores, why other parts of the body are not affected, and how treatment may work. It has been 24 years since rapamycin (sirolimus) was approved to mitigate solid organ transplant rejection and 16 years since mTOR (mammalian/mechanistic target of rapamycin) inhibitors reached patients as a cancer therapy. While the clinical benefits of mTOR inhibitors (mTORi) are robust, so too are their toxicities. Among the most common issues is the development of ulcers of the oral mucosa (mTOR-inhibitor associated stomatitis; mIAS). These lesions are distinct from those of other anti-cancer agents, occur with regularity, and impact patient outcomes. mIAS' pathogenesis has been the subject of speculation, and its similar presentation to recurrent aphthous stomatitis (RAS) has led to the hypothesis that it might serve as a surrogate to better understand RAS. Based on a review of the literature, the current manuscript provides a hypothesis regarding the mechanisms by which mTORis uniquely initiate mucosal injury and an explanation for the observation that steroids (also an immunosuppressive) are effective in its treatment through a non-immunologic mechanism. Unexplained unique features of mIAS are discussed in this review in the context of future investigation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
231. Everolimus Acts in Synergy with Vinorelbine to Suppress the Growth of Hepatocellular Carcinoma.
- Author
-
Huynh, Hung, Ng, Wai Har, and Soo, Khee Chee
- Subjects
- *
EVEROLIMUS , *HEPATOCELLULAR carcinoma , *VINORELBINE , *SURVIVIN (Protein) , *RAPAMYCIN , *MTOR inhibitors - Abstract
Hepatocellular carcinoma (HCC) is a challenging cancer to treat, as traditional chemotherapies have shown limited effectiveness. The mammalian target of rapamycin/sirolimus (mTOR) and microtubules are prominent druggable targets for HCC. In this study, we demonstrated that co-targeting mTOR using mTOR inhibitors (everolimus and sirolimus) along with the microtubule inhibitor vinorelbine yielded results superior to those of the monotherapies in HCC PDX models. Our research showed that the vinorelbine arrests cells at the mitotic phase, induces apoptosis, and normalizes tumor blood vessels but upregulates survivin and activates the mTOR/p70S6K/4EBP1 pathway. The addition of the everolimus significantly improved the tumor response to the vinorelbine, leading to improved overall survival (OS) in most tested orthotopic HCC PDX models. The mechanistic investigation revealed that this marked antitumor effect was accompanied by the downregulations of mTOR targets (p-p70S6K, p-4EBP1, and p-S6K); several key cell-cycle regulators; and the antiapoptotic protein survivin. These effects did not compromise the normalization of the blood vessels observed in response to the vinorelbine in the vinorelbine-sensitive PDX models or to the everolimus in the everolimus-sensitive PDX models. The combination of the everolimus and vinorelbine (everolimus/vinorelbine) also promoted apoptosis with minimal toxicity. Given the cost-effectiveness and established effectiveness of everolimus, and especially sirolimus, this strategy warrants further investigation in early-phase clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
232. The association between computed tomography attenuation value of renal angiomyolipoma associated with tuberous sclerosis complex and response to everolimus.
- Author
-
Liao, Zhangcheng, Li, Jiao, Zhao, Yang, Wang, Zhan, Wang, Xu, Qiu, Dongxu, and Zhang, Yushi
- Abstract
Background: The response to everolimus in patients with renal angiomyolipoma associated with tuberous sclerosis complex (TSC-RAML) varies among individuals. This study aims to identify potential factors associated with the response to everolimus. Method: We retrospectively examined data encompassing age, gender, tumor size, computed tomography attenuation value (CT value), CT enhancement, and tumor reduction rate in patients with TSC-RAML undergoing everolimus in two previously registered clinical trials. Result: A total of 33 participants (29.33 ± 6.63 years old, 20 females) were included. The correlation analysis conducted separately for tumors located in the left and right kidneys revealed significant negative correlations (P < 0.05) between tumor reduction rate and age, as well as tumor size. While significant positive correlations (P < 0.05) were observed between tumor reduction rate and unenhanced CT value as well as CT enhancement. Nonetheless, based on multiple linear regression analysis, unenhanced CT value emerged as the sole-independent predictor of tumor reduction rate among age, gender, tumor size, unenhanced CT value and CT enhancement for both left (coefficient = 0.00319, P < 0.0001) and right kidneys (coefficient = 0.00315, P = 0.0104). Notable reductions were observed in unenhanced CT value (− 3.81 vs − 24.70HU, P < 0.0001) and CT enhancement (48.16 vs 33.56HU, P < 0.0001) following a 3-month administration of everolimus. The decline in both unenhanced CT value and tumor size predominantly occurred within the initial 3 months, subsequently maintaining a relatively stable level throughout the treatment. Conclusion: The unenhanced CT value of TSC-RAML showed an independent correlation with the response to everolimus, suggesting its potential as a predictor of everolimus efficacy in patients with TSC-RAML. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
233. Impact of the PI3K-alpha inhibitor alpelisib on everolimus resistance and somatostatin receptor expression in an orthotopic pancreatic NEC xenograft mouse model.
- Author
-
Mohan, Ajay-Mohan, Prasad, Sonal, Schmitz-Peiffer, Fabian, Lange, Catharina, Lukas, Mathias, Koziolek, Eva J., Albrecht, Jakob, Messroghli, Daniel, Stein, Ulrike, Ilmer, Matthias, Wang, Katharina, Schober, Laura, Reul, Astrid, Maurer, Julian, Friemel, Juliane, Weber, Achim, Zuellig, Richard A., Hantel, Constanze, Fritsch, Ralph, and Reincke, Martin
- Subjects
- *
EVEROLIMUS , *SOMATOSTATIN receptors , *LABORATORY mice , *ANIMAL disease models , *NEUROENDOCRINE tumors , *ORAL drug administration - Abstract
The mechanistic target of rapamycin complex 1 (mTORC1) inhibitor everolimus is one of the few approved therapies for locally advanced and metastatic neuroendocrine tumours (NETs). However, after initial disease stabilisation, most patients develop resistance within 1 year. Our aim was to overcome resistance to everolimus by additional treatment with the PI3K-alpha inhibitor alpelisib in an everolimus-resistant orthotopic pancreatic neuroendocrine carcinoma xenograft mouse model. Female SCID mice underwent laparoscopic pancreatic transplantation of everolimus-sensitive (BON1KDMSO) or everolimus-resistant (BON1RR2) NET cells. Both groups were further divided into four treatment groups: placebo, everolimus, alpelisib, and everolimus + alpelisib (combination). Oral treatment was started at a tumour volume of approximately 140 mm3 and continued until 1900-2000 mm3, validated by weekly MRI. Somatostatin receptor expression and tumour viability were analysed by 68Ga-DOTATOC and 18F-FDG PET/CT. Everolimus resistance of the BON1RR2 tumours was confirmed. In the everolimus-sensitive group, everolimus alone, alpelisib alone, and combination treatment significantly prolonged survival, compared to placebo, while in the BON1RR2 group, only combination treatment significantly prolonged survival compared to placebo, but neither everolimus nor alpelisib alone. Placebo-treated everolimus-sensitive tumours grew more rapidly (median survival 45 days), compared to placebo-treated everolimus-resistant tumours (60 days). Within the everolimus-sensitive group, the combination-treated mice showed the longest median survival (52 days). Of all groups, the everolimus-resistant combination-treated group survived longest (69 days). Combination treatment with everolimus and alpelisib seems promising to overcome everolimus resistance in neuroendocrine neoplasms, and should be further examined in a clinical trial. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
234. Effect of everolimus combined with anastrozole on serum FOXP 3 and MMP 9 in hormone receptor-positive elderly breast cancer patients.
- Author
-
Shaofen Hu, Zhiling Li, and Qin Chen
- Subjects
- *
ANASTROZOLE , *HORMONE receptor positive breast cancer , *SCURFIN (Protein) , *EVEROLIMUS , *BLOOD serum analysis , *DISEASE incidence - Abstract
Breast cancer currently leads among all the types of cancer in the total nmber of estimated cases worldwide, and holds fourth position in total number of deaths caused by cancer. It calls for early diagnosis and an effective treatment. Here, we explored the effect of everolimus combined with anastrozole treatment on the prognosis and serum FOXP 3 and matrix metalloproteinase 9 (MMP 9) in hormone receptor (HR) positive elderly breast cancer patients. A total of 96 elderly patients with HR positive breast cancer admitted to the hospital from April 2018 to April 2021 were selected and divided into two groups according to the random number table method. The control group (n=48) was given anastrozole, and the study group (n=48) was given everolimus and anastrozole. Recent efficacy, estrogen, adverse effects, survival rate, and test serum FOXP 3, MMP 9 levels were recorded. The results showed higher objective response rate (ORR) as (62.5%, 30/48) (41.67%, 20/48) (P <0.05), 1-year survival rate as (91.67%, 44/48) (75%, 36/48) (P <0.05), and stomatitis as (25%, 12/48) (8.33%, 4/48) (P <0.05). After treatment, estradiol (E2), luteinizing hormone (LH), FOXP 3, and MMP 9 were lower than before treatment (P <0.05), and the study group was lower than the control group (P <0.05). It has been concluded that everolimus and anastrozole therapy in HR positive elderly breast cancer can reduce estrogen and serum FOXP 3 and MMP 9 levels, with high 1-year survival rate, but with high incidence of stomatitis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
235. Gelatin microgel-coated balloon catheter with enhanced delivery of everolimus for long-term vascular patency.
- Author
-
Lee, Simin, Yoon, Chang-Hwan, Oh, Dong Hwan, Anh, Tu Quang, Jeon, Ki-Hyun, Chae, In-Ho, and Park, Ki Dong
- Subjects
VASCULAR endothelial cells ,DRUG delivery systems ,PERCUTANEOUS coronary intervention ,VASCULAR smooth muscle ,EVEROLIMUS ,ETHANOL ,ENDOTHELIUM ,RETINAL blood vessels - Abstract
In-stent restenosis (ISR) after percutaneous coronary intervention is a major reason for limited long-term patency due to complex neointimal proliferation caused by vascular injury. Drug-coated balloon (DCB) has been developed to treat various cardiovascular diseases including ISR by providing anti-proliferative drugs into blood vessel tissues. However, a significant proportion of the drug is lost during balloon tracking, resulting in ineffective drug delivery to the target region. In this study, we report an everolimus-coated balloon (ECB) using everolimus-loaded gelatin-hydroxyphenyl propionic acid microgel (GM) with enhanced everolimus delivery to vascular walls for long-term patency. GM with high drug loading (> 97%) was simply prepared by homogenizing enzyme-mediated crosslinked hydrogels. The optimal condition to prepare GM-coated ECB (GM-ECB) was established by changing homogenization time and ethanol solvent concentration (30 ∼ 80%). In vitro sustained everolimus release for 30 d, and cellular efficacy using smooth muscle cells and vascular endothelial cells were evaluated. Additionally, an in vivo drug transfer levels of GM-ECB using rabbit femoral arteries were assessed with reduced drug loss and efficient drug delivery capability. Finally, using ISR-induced porcine models, effective in vivo vascular patency 4 weeks after treatment of ECBs was also confirmed. Thus, this study strongly demonstrates that GM can be used as a potential drug delivery platform for DCB application. We report an ECB using everolimus-loaded GM prepared by homogenization of enzymatic cross-linked hydrogel. GM showed efficient drug loading (> 97 %) and controllable size. GM-ECB exhibited potential to deliver everolimus in a sustained manner to target area with drug efficacy and viability against SMC and EC. Although GM-ECB had much lower drug content compared to controls, animal study demonstrated enhanced drug transfer and reduced drug loss of GM-ECB due to the protection of encapsulated drugs by GM, and the possible interaction between GM and endothelium. Finally, vascular patency and safety were assessed using ISR-induced porcine models. We suggest an advanced DCB strategy to alleviate rapid drug clearance by bloodstream while improving drug delivery for a long-term vascular patency. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
236. Clinical significance of mechanistic target of rapamycin expression in vessels that encapsulate tumor cluster‐positive hepatocellular carcinoma patients who have undergone living donor liver transplantation.
- Author
-
Toshida, Katsuya, Itoh, Shinji, Toshima, Takeo, Yoshiya, Shohei, Goto, Ryoichi, Mita, Atsuyoshi, Harada, Noboru, Kohashi, Kenichi, Oda, Yoshinao, and Yoshizumi, Tomoharu
- Subjects
LIVER transplantation ,RAPAMYCIN ,MTOR protein ,PATIENT experience ,IMMUNOSTAINING - Abstract
Background: There is limited published information regarding the expression of mechanistic target of rapamycin (mTOR) in vessels that encapsulate tumor cluster (VETC)‐positive hepatocellular carcinoma (HCC). The mTOR inhibitor, everolimus, has been approved as an immunosuppressant for use in HCC patients after living donor liver transplantation (LDLT). Methods: Using a database of 214 patients who underwent LDLT for HCC, we examined the mTOR protein and angiopoietin‐2 (Ang‐2) in VETC‐positive HCC by immunohistochemical staining. The presence of VETC and mTOR expression were evaluated in both primary and recurrent HCC lesions. Results: Forty‐three of the 214 patients (20.1%) were VETC‐positive, and 29 of these 43 patients (67.4%) expressed mTOR. Relative Ang‐2 expression was significantly higher in the mTOR‐positive than in the mTOR‐negative group (p = 0.037). Thirty‐four of the 214 patients experienced HCC recurrence after LDLT; 20 of these were operable. The primary lesions of six of these 20 patients were VETC‐positive; five of these six patients also had VETC‐positive recurrent lesions (p < 0.001). The expression of mTOR was significantly higher in the VETC‐positive lesions (p = 0.0018). Conclusions: We showed that mTOR expression was higher in the VETC‐positive primary and recurrent lesions than in the VETC‐negative ones. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
237. Everolimus-encapsulation in Pluronic P123 self-assembled micelles as drug delivery systems for drug-coated balloons
- Author
-
Mohammad Akrami-Hasan-Kohal, Adrien Chouchou, Sébastien Blanquer, and Tahmer Sharkawi
- Subjects
Drug-coated balloons ,Everolimus ,Pluronic P123 ,Micelles ,Excipient ,Drug delivery ,Pharmacy and materia medica ,RS1-441 - Abstract
Drug-coated balloons (DCBs) are effective tools for cardiovascular interventions, ensuring uniform drug delivery to occluded arteries. This research investigates the potential of Pluronic P123 (P123), a micelle-forming polymer, to solubilize and release Everolimus (EVE) from DCBs. Furthermore, it seeks to understand how the ratio of P123 to EVE affects release rates and micelle formation under physiological conditions. We tested three P123 to EVE ratios: 90:10, 75:25, and 50:50. Microscopy revealed that increasing EVE proportions resulted in more uniform coatings. Fourier-transform infrared spectroscopy (FTIR) analysis confirmed the successful incorporation of EVE into the P123 matrix without altering its chemical properties. Differential scanning calorimetry (DSC) studies showed that EVE incorporation affected the crystalline structure of P123, leading to more uniform coatings. In vitro release studies showed that all formulations had
- Published
- 2024
- Full Text
- View/download PDF
238. The prognosis of patients treated with everolimus for advanced ER‐positive, HER2‐negative breast cancer is driven by molecular features
- Author
-
Hélène Salaün, Lounes Djerroudi, Laura Haik, Anne Schnitzler, Guillaume Bataillon, Gabrielle Deniziaut, Ivan Bièche, Anne Vincent‐Salomon, Marc Debled, and Paul Cottu
- Subjects
everolimus ,biomarkers ,luminal metastatic breast cancer ,prognosis ,Pathology ,RB1-214 - Abstract
Abstract Everolimus is widely used in patients with advanced ER‐positive, HER2‐negative breast cancer. We looked at alterations in the PIK3CA/AKT/mTOR pathway in a multicenter cohort as potential biomarkers of efficacy. Patients with advanced ER‐positive, HER2‐negative breast cancer treated with everolimus and endocrine therapy between 2012 and 2014 in two cancer centers were included. Targeted sequencing examined mutations in PIK3CA, ESR1, and AKT1 genes. An immunochemical analysis was conducted to evaluate expression of PTEN, INPP4B, STK11, p4EBP1, and pS6. We analyzed 71 patients (44 primary tumors; 27 metastatic tissues). Median age was 63 years [58–69]. All patients had heavily pretreated advanced disease. A mutation in the PIK3CA pathway was observed in 32 samples (PIK3CA exons 10 and 21 and AKT1 exon 4 in 15.5%, 24.0%, and 5.6% of samples), and in ESR1 in 5 samples (7.0%), respectively. Most samples showed cytoplasmic expression of the PIK3CA pathway proteins. Progression‐free survival was longer in patients with a pS6 or p4EBP1 histoscore ≥ median value (6.6 versus 3.7 months, p = 0.037), and in patients with a PTEN histoscore ≤ median value (7.1 versus 5.3 months, p = 0.02). Overall survival was longer in patients with pS6 ≥ 3rd quartile (27.6 versus 19.3 months, p = 0.038) and in patients with any mutation in the PIK3CA/AKT/mTOR pathway (27.6 versus 19.3 months, p = 0.011). The prognosis of patients treated with everolimus for advanced ER‐positive, HER2‐negative breast cancer appears primarily driven by molecular features associated with the activation of the PIK3CA/AKT/mTOR pathway.
- Published
- 2024
- Full Text
- View/download PDF
239. Everolimus decreases [U-13C]glucose utilization by pyruvate carboxylase in breast cancer cells in vitro and in vivo
- Author
-
Gerke Ariaans, Jiske F. Tiersma, Bernardus Evers, Albert Gerding, Stijn J.H. Waaijer, Remco A. Koster, Daan J. Touw, Barbara M. Bakker, Dirk-Jan Reijngoud, Steven de Jong, and Mathilde Jalving
- Subjects
Metformin ,Everolimus ,Cancer metabolism ,Breast cancer ,[U-13C]glucose ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Reprogrammed metabolism is a hallmark of cancer, but notoriously difficult to target due to metabolic plasticity, especially in response to single metabolic interventions. Combining mTOR inhibitor everolimus and mitochondrial complex 1 inhibitor metformin results in metabolic synergy in in vitro models of triple-negative breast cancer. Here, we investigated whether the effect of this drug combination on tumor size is reflected in changes in tumor metabolism using [U-13C]glucose labeling in an MDA-MB-231 triple negative breast cancer xenograft model. The in vitro effects of everolimus and metformin treatment on oxidative phosphorylation and glycolysis reflected changes in 13C-labeling of metabolites in MDA-MB-231 cells. Treatment of MDA-MB-231 xenografts in SCID/Beige mice with everolimus resulted in slower tumor growth and reduced tumor size and tumor viability by 35%. Metformin treatment moderately inhibited tumor growth but did not enhance everolimus-induced effects. High serum levels of everolimus were reached, whereas levels of metformin were relatively low. Everolimus decreased TCA cycle metabolite labeling and inhibited pyruvate carboxylase activity. Metformin only caused a mild reduction in glycolytic metabolite labeling and did not affect pyruvate carboxylase activity or TCA cycle metabolite labeling. In conclusion, treatment with everolimus, but not metformin, decreased tumor size and viability. Furthermore, the efficacy of everolimus was reflected in reduced 13C-labeling of TCA cycle intermediates and reduced pyruvate carboxylase activity. By using in-depth analysis of drug-induced changes in glucose metabolism in combination with measurement of drug levels in tumor and plasma, effects of metabolically targeted drugs can be explained, and novel targets can be identified.
- Published
- 2024
- Full Text
- View/download PDF
240. Randomized Comparison of Abluminus DES+ Sirolimus-Eluting Stents Versus Everolimus-Eluting Stents in Coronary Artery Disease Patients With Diabetes Mellitus Global (ABILITY)
- Published
- 2023
241. Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer
- Published
- 2023
242. Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors
- Published
- 2023
243. Phase I/II Trial of Everolimus in Combination With Lonafarnib in Progeria
- Author
-
Monica E. Kleinman, Medical Director, Transport & MSICU
- Published
- 2023
244. Efficacy and Safety of Everolimus and (STZ-5FU) Given One Upfront the Other Upon Progression in Advanced Pancreatic Neuroendocrine Tumor (pNET) (SEQTOR)
- Author
-
European Neuroendocrine Tumor Society, Kantar Health, and Novartis Pharmaceuticals
- Published
- 2023
245. Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer (EVIDENT)
- Author
-
Tormod Kyrre Guren, MD, Principal Investigator
- Published
- 2023
246. Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy (Treat ER+ight)
- Published
- 2023
247. STACCATO: Stent sTrut Apposition and Coverage in Coronary ArTeries: an Optical Coherence Tomography (OCT) Study (STACCATO)
- Published
- 2023
248. SEDUCE OCT Study in Coronary Artery rEstenosis:an Optical Coherence Tomography (OCT) Study (SEDUCE)
- Published
- 2023
249. A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease
- Author
-
Merck Sharp & Dohme LLC
- Published
- 2023
250. A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)
- Author
-
Novartis
- Published
- 2023
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.